In an intriguing study, researchers found that patients with a family history of colorectal cancer, once treated, live longer than patients without a family history of the disease. What is more, the risk is further reduced by having an increasing number of affected first-degree relatives, according to a study in the June 4 issue of JAMA.
Approximately 16 percent to 20 percent of patients with colorectal cancer have a first-degree relative with the disease.
In the general population, there is a 5 percent to 6 percent chance of developing colon cancer and this risk is doubled in those with a familial link to the disease, Jennifer A. Chan, M.D., M.P.H. of the Dana-Farber Cancer Institute in Boston told DOTmed.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
However, the chance that the tumor will return is 28 percent less in those with a familiar link than in those who have no family history of the disease, she says.
Dr. Chan says this finding did not surprise her as she had hypothesized that patients with a familial link to the disease have a better prognosis.
But while she had seen some hereditary forms of colon cancer in which patients had a favorable prognosis, she had only anecdotal evidence to back up her hunch.
To prove her hypothesis, she and her and colleagues examined 1,087 patients with stage III colon cancer who had undergone surgery and were receiving chemotherapy. She followed them for five and a half years.
In addition to finding that those with a familial link to the disease had a 28 percent lower risk of recurrence or dying, she found that patients with two or more affected relatives had a 51 percent lower risk for cancer recurrence or death than those with no family history of the disease.
And when she looked for just the risk for cancer recurrence, she found that patients with a family history of the disease had a 26 percent reduced risk compared to others during the time they were followed.
She says that the form of colorectal cancer linked to family history behaves differently because of something biologic, "but we just don't know what it is."
In a JAMA editorial, Boris Pasche, M.D., PHD, of the Northwestern University Feinberg School of Medicine, Chicago and contributing Editor, JAMA, commented on the results of the study.
He said that if these findings are validated in future studies, family history may become a new prognostic factor in treating colon cancer. He said tumor gene expression profiling studies would have to be conducted to see which tumors respond to chemotherapy and which do not.